Table 1. Proliferation of Elesclomol-treated HEMs and melanoma cells.
| 20% O2 no CuCl2 (nM; 95CI) | 20% O2 5 µM CuCl2 (nM; 95CI) | 0.1% O2, no CuCl2 (nM; 95CI) | |
| HEMs | >500 | 216 (18–2,612) | |
| WM983-A | 59 (5–782) | 7 (1–38) | 54 (12–247) |
| WM983-ACyQUANT | 79 (23–267) | 4 (2–12) | |
| WM983-B | 47 (6–391) | 26 (4–192) | 63 (11–373) |
| WM983-BCyQUANT | 90 (40–203) | 2 (1–6) | |
| WM1158 | 31 (10–93) | 11 (3–42) | 34 (6–183) |
| WM852 | 14 (4–48) | 6 (1–32) | 30 (12–79) |
| MV3 | 110 (27–446) | 5 (1–19) | 164 (90–300) |
| TPF 10–741 | >500 | 3 (1–11) | >500 |
| TPF 11–43 | 59 (26–133) | 23 (6–85) | 116 (53–256) |
| Lu1205 | 6 (1–67) | 1 (0.1–5) | 37 (2–578) |
Cells were grown for three days in 20% O2 in the absence or presence of CuCl2 (5 µM), or under hypoxic conditions (0.1% O2). Depicted are mean IC50 values for Elesclomol with 95% confidence intervals (95 CI) under each of the three conditions. ND - not determined.